<?all-math-mml yes?>
<?use-mml?>
<?properties open_access?>
<?properties manuscript?>
<?origin nihpa?>
<?iso-abbr Nat. Methods?>
<?submitter-system nihms?>
<?submitter-canonical-name Nature Publishing Group?>
<?submitter-canonical-id NATURE-STRUCTUR?>
<?submitter-userid 8068858?>
<?submitter-authority myNCBI?>
<?submitter-login nature-structure?>
<?submitter-name Nature Publishing Group?>
<?domain nihpa?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-journal-id">101215604</journal-id>
    <journal-id journal-id-type="pubmed-jr-id">32338</journal-id>
    <journal-id journal-id-type="nlm-ta">Nat Methods</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nat. Methods</journal-id>
    <journal-title-group>
      <journal-title>Nature methods</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1548-7091</issn>
    <issn pub-type="epub">1548-7105</issn>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">6231406</article-id>
    <article-id pub-id-type="pmid">29457793</article-id>
    <article-id pub-id-type="doi">10.1038/nmeth.4606</article-id>
    <article-id pub-id-type="manuscript">nihpa937763</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Identifying the Favored Mutation in a Positive Selective Sweep</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Akbari</surname>
          <given-names>Ali</given-names>
        </name>
        <xref ref-type="aff" rid="A1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Vitti</surname>
          <given-names>Joseph J.</given-names>
        </name>
        <xref ref-type="aff" rid="A2">2</xref>
        <xref ref-type="aff" rid="A3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Iranmehr</surname>
          <given-names>Arya</given-names>
        </name>
        <xref ref-type="aff" rid="A1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bakhtiari</surname>
          <given-names>Mehrdad</given-names>
        </name>
        <xref ref-type="aff" rid="A4">4</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sabeti</surname>
          <given-names>Pardis C.</given-names>
        </name>
        <xref ref-type="aff" rid="A2">2</xref>
        <xref ref-type="aff" rid="A3">3</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mirarab</surname>
          <given-names>Siavash</given-names>
        </name>
        <xref ref-type="aff" rid="A1">1</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bafna</surname>
          <given-names>Vineet</given-names>
        </name>
        <xref ref-type="aff" rid="A4">4</xref>
      </contrib>
    </contrib-group>
    <aff id="A1"><label>1</label>Department of Electrical &amp; Computer Engineering, University of California San Diego, La Jolla, California, USA</aff>
    <aff id="A2"><label>2</label>Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, USA</aff>
    <aff id="A3"><label>3</label>Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA</aff>
    <aff id="A4"><label>4</label>Department of Computer Science &amp; Engineering, University of California San Diego, La Jolla, California, USA</aff>
    <author-notes>
      <fn fn-type="con" id="FN1">
        <p id="P1"><bold>Author contributions.</bold> A.A., S.M., and V.B. conceived and designed the experiments and wrote the manuscript with input from all authors; A.A., J.J.V., and A.I. performed the experiments; A.A. analyzed the data. A.A. and M.B. developed software tools; P.C.S., S.M., and V.B. provided guidance throughout the study.</p>
      </fn>
      <corresp id="CR1">Correspondence should be addressed to A.A.(<email>alakbari@ucsd.edu</email>) or V.B. (<email>vbafna@ucsd.edu</email>).</corresp>
    </author-notes>
    <pub-date pub-type="nihms-submitted">
      <day>30</day>
      <month>10</month>
      <year>2018</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>19</day>
      <month>2</month>
      <year>2018</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <month>4</month>
      <year>2018</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>12</day>
      <month>11</month>
      <year>2018</year>
    </pub-date>
    <volume>15</volume>
    <issue>4</issue>
    <fpage>279</fpage>
    <lpage>282</lpage>
    <!--elocation-id from pubmed: 10.1038/nmeth.4606-->
    <permissions>
      <license>
        <license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p>
      </license>
    </permissions>
    <abstract id="ABS1">
      <p id="P2">Methods to identify signatures of selective sweeps in population genomics data have been actively developed, but mostly do not identify the specific mutation favored by selection. We present a method, iSAFE, that uses a statistic derived solely from population genetics signals to accurately pinpoint the favored mutation in a large region (~5 Mbp). iSAFE does not require any knowledge of demography, specific phenotype under selection, or functional annotations of mutations.</p>
    </abstract>
  </article-meta>
</front>
<body>
  <p id="P3">Human genetic data have revealed a multitude of genomic regions believed to be evolving under positive selection. Methods for detecting regions under selection from genetic variations exploit a variety of genomic signatures. Allele frequency based methods analyze the distortion in site frequency spectrums; Linkage Disequilibrium (LD) based methods use extended homozygosity in haplotypes; other methods use differences in allele frequency between populations; and finally, composite methods combine multiple test scores to improve the resolution<sup><xref rid="R1" ref-type="bibr">1</xref>–<xref rid="R3" ref-type="bibr">3</xref></sup>. Recently, a lack of rare (singleton) mutations has been used to detect very recent selection<sup><xref rid="R4" ref-type="bibr">4</xref></sup>. The signature of a selective sweep can be captured even when standing variation or multiple <italic>de novo</italic> mutations create a ‘soft’ sweep of distinct haplotypes carrying the favored mutation. Paired with deep sequencing data, these methods have identified multiple regions believed to be under selection, and provide a window into genetic adaptation and evolution.</p>
  <p id="P4">In contrast, little work has been done to identify the favored mutation in a selective sweep. Grossman et al.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> note that different selection signals identify overlapping but different regions, and a composite of multiple signals (CMS) can localize the site of the favored mutation. An alternative strategy is to use rank SNPs based on their functional annotations. However, the signal of selection is often spread over regions up to 1–2 Mbp on either side<sup><xref rid="R3" ref-type="bibr">3</xref></sup>, and the high LD makes it difficult to pinpoint the favored mutation. Here, we propose a method, iSAFE (<underline>i</underline>ntegrated <underline>S</underline>election of <underline>A</underline>llele <underline>F</underline>avored by <underline>E</underline>volution), that exploits coalescent-based signals in ‘shoulders’<sup><xref rid="R3" ref-type="bibr">3</xref></sup> of the selective sweep (genomic regions proximal to the region under selection, but carrying the selection signal) to rank all mutations within a large (5 Mbp) region based on their contribution to the selection signal.</p>
  <p id="P5">Haplotype Allele Frequency (HAF) score is a haplotypic score that aims to separate carrier haplotypes from non-carriers without knowing the favored mutation<sup><xref rid="R6" ref-type="bibr">6</xref></sup>. Based on properties of the HAF-score, we develop a SAFE-score (see <xref rid="S1" ref-type="sec">Online Methods</xref> and <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 1</xref>; <xref rid="F1" ref-type="fig">Fig. 1a,b</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 1</xref>) that tends to be maximized for the favored mutation in a small region (50 kbp), but the performance decays when larger regions are investigated. To address the more general case of large regions (~5 Mbp) under selection, we developed the iSAFE-score, which uses a 2-step procedure to identify the favored variant. In the first step, it finds the best candidate mutations in small (low recombination) windows using the SAFE-score. Then, it combines SAFE-scores of all variants over all windows to give an iSAFE-score to each variant in the large region (see <xref rid="S1" ref-type="sec">Online Methods</xref> and <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 1</xref>; <xref rid="F2" ref-type="fig">Fig. 2a,b</xref>).</p>
  <p id="P6">The main alternatives to iSAFE are Composite of Multiple Signals (CMS)<sup><xref rid="R5" ref-type="bibr">5</xref></sup>, and Selection detection by Conditional Coalescent Tree (SCCT)<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. CMS combines statistics from different selection tests, including the integrated Haplotype Score (iHS)<sup><xref rid="R8" ref-type="bibr">8</xref></sup>, so as to localize the signal. In order to develop a unified probabilistic model, CMS expects control populations as input, as well as demographic models, and cannot be run using only the SNP matrix. Therefore, we first compared SAFE against iHS and SCCT in simulations. The median SAFE rank of the favored mutation in a 50 kbp region was 1 out of ∼250 variants (<xref rid="F1" ref-type="fig">Fig. 1c</xref>, left), and the favored mutation ranked among the top 5 in 91% of simulations. In comparison, the median ranks of iHS and SCCT were 6 and 3, respectively. The SAFE-score performance remained robust to a large range of parameter choices (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref>). However, in testing with increasing window sizes, we observed that the median rank increases beyond 80 kbp, perhaps because of the confounding signal at the shoulders of the selective sweep (<xref rid="F2" ref-type="fig">Fig. 2c</xref>).</p>
  <p id="P7">iSAFE, unlike SAFE, is specifically designed to exploit signal from the shoulders of the sweep (see <xref rid="S1" ref-type="sec">Online Methods</xref> and <xref rid="F2" ref-type="fig">Fig. 2a,b</xref>). iSAFE showed consistently high performance as the window size was increased from 250 kbp all the way to 5 Mbp (<xref rid="F2" ref-type="fig">Fig. 2c</xref>). The median rank remained between 3 and 5 up to 5 Mbp, and the performance remained robust to a large range of parameter choices (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3–6</xref>). iSAFE greatly improved upon iHS and SCCT, placing the favored mutation within top 20 in 88% of the cases, in contrast to iHS (39%), and SCCT (34%), for an ongoing selective sweep with fixed population size (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3</xref>).</p>
  <p id="P8">Not surprisingly, iSAFE performance deteriorates when the favored mutation is fixed, or near fixation (favored allele frequency (<italic>ν</italic>) &gt; 0.9 in <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3</xref>). To handle this special case, we include individuals from non-target populations using a specific protocol (see <xref rid="S1" ref-type="sec">Online Methods</xref>). Subsequently, the performance remained unchanged for <italic>ν</italic> &lt; 0.9 and dramatically improved for high frequencies, including when the favored mutation was fixed in the target population (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3</xref>). We also tested iSAFE against CMS using a model of human demography. While CMS showed excellent performance in localizing the favored mutation, iSAFE scoring greatly improved the ranking. For example, iSAFE ranked the favored mutation within the top 20 in 94% of the simulations of a 5 Mbp region (<xref rid="F3" ref-type="fig">Fig. 3a</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 4</xref>), in contrast to CMS, which had a top 20 ranking in 35% of cases.</p>
  <p id="P9">iSAFE-scores are not based upon likelihood computations, and we use them primarily to rank order the mutations. However, iSAFE-scores are normalized and can be compared across samples. Empirically computed <italic>P</italic> values (see <xref rid="S1" ref-type="sec">Online Methods</xref>) on iSAFE indicate good performance when <italic>P</italic> &lt; 1e-4, (iSAFE ≥ 0.1; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 7</xref>).</p>
  <p id="P10">We tested iSAFE performance on 22 human loci previously characterized as containing signatures of a selective sweep (<xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>), with some evidence for the favored mutation. The list included 8 ‘well characterized’ cases with additional support for the favored mutation (<xref rid="SD3" ref-type="supplementary-material">Supplementary Table 1</xref>). Using genotype data from phase 3 of 1000 Genomes Project (1000GP)<sup><xref rid="R9" ref-type="bibr">9</xref></sup> sub-populations, we used iSAFE to rank all variants (∼21,000) in a 5 Mbp region surrounding each locus. Among the 8 well characterized cases<sup><xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R10" ref-type="bibr">10</xref>–<xref rid="R14" ref-type="bibr">14</xref></sup> (<xref rid="F3" ref-type="fig">Fig. 3b</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 8</xref>), iSAFE ranked the candidate mutations as 1 in 5 cases: SLC24A5, LCT, EDAR, ACKR1, TLR1, and ranked the remaining as 2 (ABCC1), 4 (HBB), and 13 (G6PD).</p>
  <p id="P11">We checked whether the other 14 loci<sup><xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R15" ref-type="bibr">15</xref>–<xref rid="R18" ref-type="bibr">18</xref></sup> under selection showed a strong iSAFE signal (<xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>). In 3 of the 14 loci (FUT2, F12, ASPM; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 9</xref>), we observed weak signals and did not make a prediction (peak iSAFE &lt; 0.027). In other loci, iSAFE ranked the candidate mutations as 1 in the SLC45A2/MATP (CEU), MC1R (CHB+JPT), and ATXN2-SHB3 (GBR) loci (<xref rid="F3" ref-type="fig">Fig. 3c</xref>), and 7, 8, and 12 in PSCA (YRI), ADH1B (CHB+JPT), and PCDH15 (CHB+JPT) loci, respectively. In each case, the iSAFE-scores were high with the exception of PSCA (peak iSAFE = 0.04, <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 9</xref>).</p>
  <p id="P12">The other 5 putative selected loci are interesting in that the top-ranked iSAFE mutations had high scores, but were distinct from the reported candidate mutations (<xref rid="F3" ref-type="fig">Fig. 3c</xref>; <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>). Many of these loci are involved in pigmentation, determining, skin, eye, and hair color. For example, the Tyrosinase (TYR) gene, encoding an enzyme involved in the first step of melanin production, is considered to be under positive selection with a nonsynonymous mutation rs1042602 as a candidate favored variant<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. A second intronic variant, rs10831496, in GRM5, 396 kbp upstream of TYR, has been shown to have a strong association with skin color<sup><xref rid="R19" ref-type="bibr">19</xref></sup>. In contrast, iSAFE ranks mutation rs672144 at the top. Interestingly, this variant was the top ranked mutation not only in CEU (iSAFE = 0.48, <italic>P</italic> ≪ 1.3e-8), but also in EUR, EAS, AMR, and SAS (iSAFE &gt; 0.5, <italic>P</italic> ≪ 1.3e-8; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 10</xref>). The result is consistent with a signal of selection present in all populations except AFR. It may not have been previously reported because it is near fixation in all populations of 1000GP except for AFR (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 10</xref>). We found that two distinct haplotypes carry the rs672144 mutation, both of which have remained at high frequency, maintained across a large stretch of the region, suggestive of a soft sweep with standing variation (<xref rid="F3" ref-type="fig">Fig. 3d</xref>). A similar analysis applied to loci TRPV6, KITLG, OCA-HERC2 (see <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>; <xref rid="F3" ref-type="fig">Fig. 3c</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 11–13</xref>), where in each case, the top iSAFE mutations were identical across all non-African populations, and supported an out-of-Africa onset of selection. In the one remaining gene (CYP1A2/CSK; see <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>; <xref rid="F3" ref-type="fig">Fig. 3c</xref>), the top ranked iSAFE mutation rs2470893 was previously found significant in a genome wide association study<sup><xref rid="R20" ref-type="bibr">20</xref></sup>, and was tightly linked to the candidate mutation. To summarize, iSAFE analysis ranked the candidate mutation among the top 13 in 14 of the 22 loci, did not show a strong signal in 3, and identified plausible alternatives in the remaining 5 (<xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>).</p>
  <p id="P13">The identification of the favored allele in a selective sweep is a long-standing problem in population genomics. Our results suggest that statistics obtained from the coalescent structure of a region under a selective sweep can indeed pinpoint the favored mutation. iSAFE performance remains robust to a range of simulation parameters, including initial frequencies (standing variation) and the frequency of the favored mutation at the time of sampling. While most results in the paper are presented on human populations, iSAFE can be easily extended to other populations as it is not highly parameterized.</p>
  <sec id="S1">
    <title>ONLINE METHODS</title>
    <p id="P14">A comprehensive explanation of the method is provided in <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 1</xref>.</p>
    <sec id="S2">
      <title>Input, output and overview.</title>
      <p id="P15">Methods to identify signatures of selective sweeps in population genomics data have been actively developed<sup><xref rid="R3" ref-type="bibr">3</xref>–<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R21" ref-type="bibr">21</xref>–<xref rid="R33" ref-type="bibr">33</xref></sup>, but mostly do not identify the specific mutation favored by selection. iSAFE uses a statistic derived solely from population genetics signals to pinpoint the favored mutation in a large region (5 Mbp), without having any knowledge of demography, specific phenotype under selection, and functional annotations of mutations. iSAFE uses a 2-step procedure to identify the favored variant, given a large region (5 Mbp) under selection. In the first step, it finds the best candidate mutations in small (low recombination) windows. Finally, it combines the evidence to give an iSAFE-score to all variants in the large region. It considers only biallelic sites, taking as input a binary SNP matrix with each row corresponding to a haplotype <italic>h</italic>, each column to a site <italic>e</italic>. Entries in the matrix correspond to the allelic state, with 0 denoting the ancestral allele, and 1 denoting the derived allele.</p>
    </sec>
    <sec id="S3">
      <title>HAF: Haplotype Allele Frequency.</title>
      <p id="P16">A haplotype ‘contains/carries a mutation <italic>e</italic>’ if it has the derived allele at site <italic>e</italic>. Recently, we devised the HAF score to capture the dynamics of a selective sweep<sup><xref rid="R6" ref-type="bibr">6</xref></sup>. The HAF score for a haplotype <italic>h</italic> (HAF(<italic>h</italic>)) is the sum of the derived allele counts of the mutations on <italic>h</italic> (see <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 1</xref>; <xref rid="F1" ref-type="fig">Fig. 1a</xref>). It has been shown that, when <italic>h</italic> is a carrier of the favored allele, HAF(<italic>h</italic>) increases with the frequency of the favored mutation (Equation SN1.9 of <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>), in contrast to HAF scores of non-carriers (Equation SN1.10 of <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>), and this can be used to separate carrier haplotypes from non-carriers without knowing the favored mutation<sup><xref rid="R6" ref-type="bibr">6</xref></sup>.</p>
    </sec>
    <sec id="S4">
      <title>SAFE: Selection of Allele Favored by Evolution.</title>
      <p id="P17">Denote two haplotypes as ‘distinct’ if they have different HAF-scores. For any mutation <italic>e</italic>, let <italic>f</italic> denote the mutation frequency, or the fraction of haplotypes carrying the mutation. Let <italic>κ</italic> (<italic>e</italic>) (<xref rid="F1" ref-type="fig">Fig. 1a</xref>) denote the fraction of distinct haplotypes that carry mutation <italic>e</italic>,</p>
      <disp-formula id="FD1">
        <label>1</label>
        <mml:math display="block" id="M1" overflow="scroll">
          <mml:mrow>
            <mml:mi>κ</mml:mi>
            <mml:mrow>
              <mml:mo>(</mml:mo>
              <mml:mi>e</mml:mi>
              <mml:mo>)</mml:mo>
            </mml:mrow>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mtext># of distinct haplotypes carrying mutation</mml:mtext>
                <mml:mo> </mml:mo>
                <mml:mi>e</mml:mi>
              </mml:mrow>
              <mml:mrow>
                <mml:mtext># of distinct haplotypes in sample</mml:mtext>
              </mml:mrow>
            </mml:mfrac>
            <mml:mo> </mml:mo>
            <mml:mo>.</mml:mo>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <p id="P18">Similarly, let <italic>ϕ</italic> (<italic>e</italic>) denote the normalized sum of HAF-scores of all haplotypes carrying the mutation <italic>e</italic>,</p>
      <disp-formula id="FD2">
        <label>2</label>
        <mml:math display="block" id="M2" overflow="scroll">
          <mml:mrow>
            <mml:mi>ϕ</mml:mi>
            <mml:mrow>
              <mml:mo>(</mml:mo>
              <mml:mi>e</mml:mi>
              <mml:mo>)</mml:mo>
            </mml:mrow>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mtext>sum of HAF-scores of haplotypes carrying mutation</mml:mtext>
                <mml:mo> </mml:mo>
                <mml:mi>e</mml:mi>
              </mml:mrow>
              <mml:mrow>
                <mml:mtext>sum of HAF-scores of all haplotypes</mml:mtext>
              </mml:mrow>
            </mml:mfrac>
            <mml:mo> </mml:mo>
            <mml:mo>.</mml:mo>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <p id="P19">We observe empirically that in a region evolving according to a neutral Wright-Fisher model, <italic>κ</italic> (<italic>e</italic>) and <italic>ϕ</italic> (<italic>e</italic>) are both estimators of <italic>f</italic> (<italic>e</italic>) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 1</xref>). Moreover, empirical results suggest that the expected value of <italic>ϕ - κ</italic> is 0, and variance is proportional to <italic>f</italic> (1 <italic>- f</italic> ). Based on these observations, we define the SAFE-score of mutation <italic>e</italic> as</p>
      <disp-formula id="FD3">
        <label>3</label>
        <mml:math display="block" id="M3" overflow="scroll">
          <mml:mrow>
            <mml:mtext>SAFE</mml:mtext>
            <mml:mrow>
              <mml:mo>(</mml:mo>
              <mml:mi>e</mml:mi>
              <mml:mo>)</mml:mo>
            </mml:mrow>
            <mml:mo>=</mml:mo>
            <mml:mfrac>
              <mml:mrow>
                <mml:mi>ϕ</mml:mi>
                <mml:mo>−</mml:mo>
                <mml:mi>κ</mml:mi>
              </mml:mrow>
              <mml:mrow>
                <mml:msqrt>
                  <mml:mrow>
                    <mml:mi>f</mml:mi>
                    <mml:mrow>
                      <mml:mo>(</mml:mo>
                      <mml:mrow>
                        <mml:mn>1</mml:mn>
                        <mml:mo>−</mml:mo>
                        <mml:mi>f</mml:mi>
                      </mml:mrow>
                      <mml:mo>)</mml:mo>
                    </mml:mrow>
                  </mml:mrow>
                </mml:msqrt>
              </mml:mrow>
            </mml:mfrac>
          </mml:mrow>
        </mml:math>
      </disp-formula>
      <p id="P20">Empirically, SAFE(<italic>e</italic>) behaves like a Gaussian random variable, with mean 0, under neutrality (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 1</xref>), and it can be used to test departure from neutrality. However, its real power appears during positive selection, when SAFE-scores change in a dramatic, but predictable manner (<xref rid="F1" ref-type="fig">Fig. 1a,b</xref>). Assuming a no recombination scenario (only for visual exposition), label mutations as ‘non-carrier’ if they are carried only by haplotypes not carrying the favored allele. The remaining mutations can be labeled as ‘ancestral’, if they arise before the favored mutation, or ‘descendant’, if they arise after (<xref rid="F1" ref-type="fig">Fig. 1b</xref>). Representing each mutation as a point in a 2-dimensional plot of <italic>ϕ</italic>, <italic>κ</italic> values, these classes are clustered differentially (<xref rid="F1" ref-type="fig">Fig. 1b</xref>). The selective sweep reduces the number of distinct haplotypes carrying the favored mutation (lower <italic>κ</italic>), leaving non-carrier mutations with an increased fraction of distinct haplotypes (higher <italic>κ</italic>). On the other hand, increased HAF-scores in carrier haplotypes reduces the proportion of total HAF-score contributed by non-carrier haplotypes (lower <italic>ϕ</italic>). In contrast, the favored mutation has high positive value of <italic>ϕ - κ</italic> due to high HAF-scores for carriers (higher <italic>ϕ</italic>), and the reduced number of distinct haplotypes among its descendants (lower <italic>κ</italic>). As we go up to ancestral mutations, the number of non-carrier haplotype descendants increase, and <italic>κ</italic> grows faster than <italic>ϕ</italic>. As we go down to descendant mutations, there is a reduction in the already small number of distinct haplotypes. However, <italic>ϕ</italic> decreases sharply, reducing <italic>ϕ - κ</italic> (<xref rid="F1" ref-type="fig">Fig. 1a,b</xref>). Thus, we expect that the mutation with the highest SAFE-score is a strong candidate for the favored mutation.</p>
      <p id="P21">We performed extensive simulations to test SAFE on samples evolving neutrally and under positive selection. We varied one parameter in each run (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref>), including window size (<italic>L =</italic> 50 kbp), number of individual haplotypes (<italic>n =</italic> 200) chosen from a larger effective population size (<italic>N =</italic> 20,000) scaled selection coefficient (<italic>Ns =</italic> 500), initial and final favored mutation frequencies (<italic>ν</italic><sub>0</sub> = 1<italic>/N</italic>, and <italic>ν</italic>). While standing variation, <italic>ν</italic><sub>0</sub> &gt; 1<italic>/N</italic>, generally weakens the selection signal, the performance of SAFE remains relatively robust to variation in <italic>ν</italic><sub>0</sub>. The median SAFE rank of the favored allele is at most 3 out of ∼250 variants in all cases except when <italic>ν</italic><sub>0</sub> &gt; 1000<italic>/N</italic> (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref>). Similarly, the performance is robust to selection pressure, with only a slight degradation at weak selection (<italic>Ns =</italic> 50) (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref>) where the median rank goes to 9 (3.5%-ile), while for <italic>Ns</italic> ≥ 200 the median rank is at most 2. As expected, the performance improves with increasing sample size (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref>). We also tested SAFE on a model of European demography and observed similar results (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 2</xref>). These tests used <italic>L =</italic> 50 kbp, chosen so as to minimize the effects of recombination.</p>
    </sec>
    <sec id="S5">
      <title>iSAFE: integrated Selection of Allele Favored by Evolution.</title>
      <p id="P22">Next, we tested SAFE with increasing window sizes, and observed that the median rank of the favored mutation increases with increasing window size (<xref rid="F2" ref-type="fig">Fig. 2c</xref>). The deterioration for larger windows is likely due to most haplotypes becoming unique, and <italic>κ</italic> losing its utility in pinpointing the favored mutation. However, the selective sweep signal is known to extend to large, linked regions, as far as 1 Mbp on either side of the favored allele. These ‘shoulders’<sup><xref rid="R3" ref-type="bibr">3</xref></sup> of selective sweeps are helpful in identifying the region under selection, but make it harder to pinpoint the favored mutation. We further refined our method to exploit the signal from shoulders.</p>
      <p id="P23">For larger regions, we considered a set of 50% overlapping windows (<inline-formula><mml:math display="inline" id="M4" overflow="scroll"><mml:mi mathvariant="script">W</mml:mi></mml:math></inline-formula>) of fixed size (300 SNPs). For each window, we applied SAFE and chose the mutation with the highest SAFE-score. Let <inline-formula><mml:math display="inline" id="M5" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="script">S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> denote the set of selected mutations. Mutations in <inline-formula><mml:math display="inline" id="M6" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="script">S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula> are likely to contain either the favored mutation itself or mutations linked to it. For mutation <italic>e</italic> in window <italic>w</italic>, let Ψ<sub><italic>e,w</italic>’</sub> denote the larger of the SAFE-score of <italic>e</italic>, when <italic>e</italic> is ‘inserted’ into window <italic>w</italic>’, and 0 (<xref rid="F2" ref-type="fig">Fig. 2a,b</xref>). As different windows have different genealogies due to recombination, Ψ<sub><italic>e,w</italic>’</sub> is relatively high when <italic>e</italic> is the favored mutation and the genealogies of <italic>w</italic>, <italic>w</italic>’ are identical or very similar, but not otherwise. In contrast, the SAFE-score of a non-favored mutation <italic>e</italic> is relatively low when inserted in other windows (see <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 1</xref>; <xref rid="F2" ref-type="fig">Fig. 2a</xref>). Define the weight of a window <italic>w</italic> as
<disp-formula id="FD4"><label>4</label><mml:math display="block" id="M7" overflow="scroll"><mml:mrow><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>e</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi mathvariant="script">S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mtext>Ψ</mml:mtext><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:msup><mml:mi>w</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>∈</mml:mo><mml:mi mathvariant="script">W</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>e</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi mathvariant="script">S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mtext>Ψ</mml:mtext><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>w</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo> </mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p>
      <p id="P24">Windows that contain the favored mutation and those sharing its genealogy are expected to have high <italic>α</italic> values. We defined the iSAFE-score for all mutations <italic>e</italic> (including those not in <inline-formula><mml:math display="inline" id="M8" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="script">S</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>) as:
<disp-formula id="FD5"><label>5</label><mml:math display="block" id="M9" overflow="scroll"><mml:mrow><mml:mtext>iSAFE</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mi>e</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munder><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>w</mml:mi><mml:mo>∈</mml:mo><mml:mi mathvariant="script">W</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mtext>Ψ</mml:mtext><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:mo>⋅</mml:mo><mml:mi>α</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>w</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo> </mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p>
      <p id="P25">iSAFE-scores are not based upon likelihood computations, and the distribution of scores depend upon largely unknown factors including demography, time since onset of selection, selection coefficient, and other parameters. Nevertheless, they can be used to rank order the mutations. Additionally, iSAFE scores are normalized and can be compared across samples. We found distinct differences in performance below a score threshold of 0.1. The median rank of the favored mutation is 4 when peak iSAFE-score exceeds 0.1 versus a median rank of 10 along with a longer tail, when peak iSAFE-score is below 0.1 (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 7</xref>). Empirically computed <italic>P</italic> values on iSAFE indicate good performance when <italic>P</italic> &lt; 1e-4 (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 7</xref>).</p>
    </sec>
    <sec id="S6">
      <title>Adding outgroup samples.</title>
      <p id="P26">Not surprisingly, iSAFE performance deteriorates when the favored mutation is fixed, or near fixation (<italic>ν</italic> &gt; 0.9 in <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3</xref>). To handle this special case, we include individuals from non-target populations. For a mutation, define the <underline>M</underline>aximum <underline>D</underline>ifference in <underline>D</underline>erived <underline>A</underline>llele <underline>F</underline>requency score (MDDAF) as
<disp-formula id="FD6"><label>6</label><mml:math display="block" id="M10" overflow="scroll"><mml:mrow><mml:mtext>MDDAF = </mml:mtext><mml:msub><mml:mi>D</mml:mi><mml:mtext>T</mml:mtext></mml:msub><mml:mtext>– min</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mtext>NT</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
Where <italic>D</italic><sub>T</sub> is the derived allele frequency in the target population and min(<bold><italic>D</italic></bold><sub>NT</sub>) is the <italic>minimum</italic> derived allele frequency over all non-target populations. Simulations of human population demography under neutral evolution shows <italic>P</italic>(MDDAF &gt; 0.78 | <italic>D</italic><sub>T</sub> &gt; 0.9) = 0.001 (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 15</xref>). Therefore, when we observe the rare event of high frequency mutations in target (<italic>D</italic><sub>T</sub> &gt; 0.9) with MDDAF &gt; 0.78, we add random outgroup samples to the data to constitute 10% of the data (<xref rid="SD3" ref-type="supplementary-material">Supplementary Note 1</xref>). In testing on the phase 3 of 1000GP data, we chose outgroup samples from non-target 1000GP populations. The addition of outgroup samples using the MDDAF criterion was tested in extensive simulations. While the performance did not change for <italic>ν</italic>&lt;0.9, it dramatically improved for high frequencies, including when the favored mutation was fixed in the target population (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 3</xref>).</p>
    </sec>
    <sec id="S7">
      <title>iSAFE evaluation.</title>
      <p id="P27">In testing on models of human demography, we also compared against CMS. While CMS showed excellent performance in localizing the favored mutation, iSAFE scoring greatly improved the ranking. For example, iSAFE ranked the favored mutation within the top 20 in 94% of the simulations of a 5 Mbp region (<xref rid="F3" ref-type="fig">Fig. 3a</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 4</xref>), in contrast to CMS which had a top 20 ranking in 35% of cases.</p>
      <p id="P28">In testing instances of previously characterized sweeps in 1000GP data, we note that performance is difficult to characterize due to many complicating factors. Multiple sweeps could be occurring in response to different selection events, including background selection in the same region; or polygenic selection may also dilute the selection signal at any one locus. Moreover, the favored mutation is well-characterized in only a few instances. We looked for genes/regions that showed the signature of a selective sweep in one of the 1000GP sub-populations, and had additional evidence pointing to the favored mutation. We identified 22 genes with some evidence, but only 8 ‘well characterized’ cases with additional support for the favored mutation (see <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>; <xref rid="SD3" ref-type="supplementary-material">Supplementary Table 1</xref>).</p>
    </sec>
    <sec id="S8">
      <title>Default simulation parameters.</title>
      <p id="P29">Neutral and sweep samples were generated using the simulator <italic>msms</italic><sup><xref rid="R34" ref-type="bibr">34</xref></sup>. By default, simulated populations are haploid with sample size of <italic>n</italic> = 200 haplotypes from a larger effective population of <italic>N</italic> = 20,000 haplotypes, each of length <italic>L</italic>, with default value 50 kbp for SAFE and 5 Mbp for iSAFE. For human populations, a mutation rate of approximately <italic>μ</italic> = 2.5e-8 mutations per bp per generation<sup><xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R35" ref-type="bibr">35</xref></sup>, and a recombination rate of approximately <italic>r</italic> = 1.25e-8 per bp per generation<sup><xref rid="R36" ref-type="bibr">36</xref></sup> have been proposed. For SAFE simulations, we used a scaled mutation rate <italic>θ</italic> = 2<italic>Nμ</italic> = 1 mutations per kbp per generation and scaled recombination rate <italic>ρ</italic> = 2<italic>Nr</italic> = 0.5 crossovers per kbp per meosis to approximate human rates. The rates were scaled linearly by <italic>L</italic>. In the case of positive selection the default scaled selection strength of the favored allele was set to <italic>Ns</italic> = 500, with the favored mutation located at a random position uniformly distributed on the range [1, <italic>L</italic>]. The default value for favored mutation starting frequency <italic>ν</italic><sub>0</sub> = 1/<italic>N</italic> (hard sweep), and the frequency of the favored mutation (<italic>ν</italic>) at the time of sampling is a random value uniformly distributed on the range [0.1, 0.9]. We used the default parameters for all simulations unless otherwise stated.</p>
    </sec>
    <sec id="S9">
      <title>A model of human demography.</title>
      <p id="P30">We simulated demography of AFR, EUR, EAS populations with parameter shown in the <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 14</xref> based on a popular demographic model of human population<sup><xref rid="R37" ref-type="bibr">37</xref></sup>. In case of positive selection, selection coefficient was set to <italic>s</italic> = 0.05 and starting favored allele frequency <italic>ν</italic><sub>0</sub> = 0.001. The time of onset of selection was chosen at random (using the distribution in <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 14</xref>) after the out of Africa event, in the lineage of EUR population (as the target population). When the onset of selection is before split of EUR and EAS (&gt; 23kya), both (EUR and EAS) are under selection.</p>
    </sec>
    <sec id="S10">
      <title>Computing iHS scores.</title>
      <p id="P31">We used the selscan<sup><xref rid="R38" ref-type="bibr">38</xref></sup> (v1.1.0a) software available at <ext-link ext-link-type="uri" xlink:href="https://github.com/szpiech/selscan">https://github.com/szpiech/selscan</ext-link>, with default settings to calculate the raw iHS<sup><xref rid="R8" ref-type="bibr">8</xref></sup> score. Next, we normalized the iHS score by estimating the distribution of raw iHS scores on 1,000 neutral simulations with the same simulation parameters. The iHS scores were always computed on a 5 Mbp window. When comparing results with SAFE on a 50 kbp window, we used the corresponding iHS scores in the identical 50 kbp region surrounding the favored variant (<xref rid="F1" ref-type="fig">Fig. 1c</xref> and <xref rid="SD2" ref-type="supplementary-material">Supplementary Figure 2</xref>). In considering 5 Mbp windows (<xref rid="SD2" ref-type="supplementary-material">Supplementary Figure 3</xref>), we compared the iHS scores on all variants for iHS against iSAFE.</p>
    </sec>
    <sec id="S11">
      <title>Computing SCCT scores.</title>
      <p id="P32">We used the SCCT (v1.1) software available at <ext-link ext-link-type="uri" xlink:href="https://github.com/wavefancy/scct">https://github.com/wavefancy/scct</ext-link>, provided by Wang et al. (2014)<sup><xref rid="R7" ref-type="bibr">7</xref></sup>, with flanking SNPs size 300, and frequency interval 0.01.</p>
    </sec>
    <sec id="S12">
      <title>Computing CMS scores.</title>
      <p id="P33">CMS<sup><xref rid="R5" ref-type="bibr">5</xref></sup> requires a control population as well as a demographic model in addition to the target population under selection. All CMS comparisons on simulated data were performed using a model of human demography<sup><xref rid="R37" ref-type="bibr">37</xref></sup> with a random onset of selection (<xref rid="SD2" ref-type="supplementary-material">Supplementary Figure 14</xref>). We used the CMS (v2.0) software available at <ext-link ext-link-type="uri" xlink:href="https://github.com/broadinstitute/cms">https://github.com/broadinstitute/cms</ext-link>, disabling CMS’ default allele frequency filter in order to allow a more direct comparison with iSAFE SNP ranking.</p>
    </sec>
    <sec id="S13">
      <title>Computing empirical <italic>P</italic> value.</title>
      <p id="P34">We applied iSAFE on a neutrally evolving simulated population with window size 5 Mbp, based on European demography shown in <xref rid="SD2" ref-type="supplementary-material">Supplementary Figure 14</xref>. A <italic>P</italic> value was calculated based on empirical distribution of iSAFE on these simulated populations. We limited the number of samples to ~74,800,000 for efficiency, and this allows us to get a <italic>P</italic> value as low as 1.34e-8 for iSAFE = 0.304. Scores higher than this cut-off are considered to have <italic>P</italic> &lt; 1.34e-8.</p>
    </sec>
    <sec id="S14">
      <title>Putative selective sweeps in human populations.</title>
      <p id="P35">We examined 8 well characterized selective sweeps with strong candidate mutation. These genes are LCT, SLC24A5, TLR1, EDAR, ACKR1/DARC, ABCC11, HBB, and G6PD. iSAFE results for these genes are summarized in <xref rid="F3" ref-type="fig">Fig. 3b</xref>, <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 8</xref> and <xref rid="SD3" ref-type="supplementary-material">Supplementary Table 1</xref>. We also examined 14 other regions reported to be under selection with one or more candidate favored mutations. A detailed report for each of these 14 loci is provided in <xref rid="SD3" ref-type="supplementary-material">Supplementary Note 2</xref>.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material" id="SM1">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="SD1">
      <label>1</label>
      <media xlink:href="NIHMS937763-supplement-1.pdf" orientation="portrait" xlink:type="simple" id="d36e1385" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD2">
      <label>2</label>
      <media xlink:href="NIHMS937763-supplement-2.docx" orientation="portrait" xlink:type="simple" id="d36e1389" position="anchor"/>
    </supplementary-material>
    <supplementary-material content-type="local-data" id="SD3">
      <label>3</label>
      <media xlink:href="NIHMS937763-supplement-3.pdf" orientation="portrait" xlink:type="simple" id="d36e1393" position="anchor"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="S15">
    <title>Acknowledgments.</title>
    <p id="P36">This research was supported in part by grants from the NSF (DBI-1458557), and from the NIH (R01GM114362).</p>
  </ack>
  <fn-group>
    <fn id="FN2">
      <p id="P37"><bold>Competing financial interests.</bold> V.B. is a co-founder, has an equity interest, and receives income from Digital Proteomics, LLC. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. D.P. was not involved in the research presented here.</p>
    </fn>
    <fn id="FN3">
      <p id="P38"><bold>Code availability.</bold> The iSAFE software and the instruction are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/alek0991/iSAFE">https://github.com/alek0991/iSAFE</ext-link> and as <bold>Supplementary Software</bold>.</p>
    </fn>
    <fn id="FN4">
      <p id="P39"><bold>Data availablity.</bold> For all the following datasets, the genome build is GRCh37/hg19. We downloaded the phased haplotypes of the 1000GP<sup><xref rid="R9" ref-type="bibr">9</xref></sup> (phase 3) dataset from <ext-link ext-link-type="uri" xlink:href="http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/">http://ftp.1000genomes.ebi.ac.uk/vol1/ftp/</ext-link> release/20130502 /. The ancestral allele dataset from Ensembl<sup><xref rid="R39" ref-type="bibr">39</xref></sup> (release 75) is downloaded from <ext-link ext-link-type="uri" xlink:href="http://ftp.ensembl.org/pub/release-75/fasta/ancestral_alleles/">http://ftp.ensembl.org/pub/release-75/fasta/ancestral_alleles/</ext-link>. The physical position was converted into genetic position using the HapMap II<sup><xref rid="R40" ref-type="bibr">40</xref></sup> genetic map downloaded from <ext-link ext-link-type="uri" xlink:href="http://ftp-trace.ncbi.nih.gov/1000genomes/ftp/technical/working/20110106_recombination_hotspots/">http://ftp-trace.ncbi.nih.gov/1000genomes/ftp/technical/working/20110106_recombination_hotspots/</ext-link>. A <bold>Life Sciences Reporting Summary</bold> is available.</p>
    </fn>
  </fn-group>
  <ref-list>
    <ref id="R1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><name><surname>Vitti</surname><given-names>JJ</given-names></name>, <name><surname>Grossman</surname><given-names>SR</given-names></name> &amp; <name><surname>Sabeti</surname><given-names>PC</given-names></name>
<source>Annual review of genetics</source>
<volume>47</volume>, <fpage>97</fpage>–<lpage>120</lpage> (<year>2013</year>).</mixed-citation>
    </ref>
    <ref id="R2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>S</given-names></name>, <name><surname>Hansen</surname><given-names>MEB</given-names></name>, <name><surname>Lo</surname><given-names>Y</given-names></name> &amp; <name><surname>Tishkoff</surname><given-names>SA</given-names></name>
<source>Science</source>
<volume>354</volume>, <fpage>54</fpage>–<lpage>59</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27846491</pub-id></mixed-citation>
    </ref>
    <ref id="R3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><name><surname>Schrider</surname><given-names>DR</given-names></name>, <name><surname>Mendes</surname><given-names>FK</given-names></name>, <name><surname>Hahn</surname><given-names>MW</given-names></name> &amp; <name><surname>Kern</surname><given-names>AD</given-names></name>
<source>Genetics</source>
<volume>200</volume>, <fpage>267</fpage>–<lpage>284</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25716978</pub-id></mixed-citation>
    </ref>
    <ref id="R4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><name><surname>Field</surname><given-names>Y</given-names></name><etal/><source>Science</source><volume>354</volume>, <fpage>760</fpage>–<lpage>764</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27738015</pub-id></mixed-citation>
    </ref>
    <ref id="R5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><name><surname>Grossman</surname><given-names>SR</given-names></name><etal/><source>Science</source><volume>327</volume>, <fpage>883</fpage>–<lpage>886</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20056855</pub-id></mixed-citation>
    </ref>
    <ref id="R6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><name><surname>Ronen</surname><given-names>R</given-names></name><etal/><source>PLoS Genet</source><volume>11</volume>, <fpage>e1005527</fpage>–<lpage>e1005527</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26402243</pub-id></mixed-citation>
    </ref>
    <ref id="R7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>M</given-names></name><etal/><source>Molecular biology and evolution</source>, <fpage>msu244</fpage>–<lpage>msu244</lpage> (<year>2014</year>).</mixed-citation>
    </ref>
    <ref id="R8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><name><surname>Voight</surname><given-names>BF</given-names></name>, <name><surname>Kudaravalli</surname><given-names>S</given-names></name>, <name><surname>Wen</surname><given-names>X</given-names></name> &amp; <name><surname>Pritchard</surname><given-names>JK</given-names></name>
<source>PLoS Biol</source>. <volume>4</volume>, <fpage>e72</fpage>–<lpage>e72</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16494531</pub-id></mixed-citation>
    </ref>
    <ref id="R9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><name><surname>Genomes Project</surname><given-names>C</given-names></name><etal/><source>Nature</source><volume>526</volume>, <fpage>68</fpage>–<lpage>74</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26432245</pub-id></mixed-citation>
    </ref>
    <ref id="R10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><name><surname>Sabeti</surname><given-names>PC</given-names></name><etal/><source>science</source><volume>312</volume>, <fpage>1614</fpage>–<lpage>1620</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16778047</pub-id></mixed-citation>
    </ref>
    <ref id="R11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><name><surname>Enattah</surname><given-names>NS</given-names></name><etal/><source>Nature genetics</source><volume>30</volume>, <fpage>233</fpage>–<lpage>237</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">11788828</pub-id></mixed-citation>
    </ref>
    <ref id="R12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><name><surname>Ohashi</surname><given-names>J</given-names></name>, <name><surname>Naka</surname><given-names>I</given-names></name> &amp; <name><surname>Tsuchiya</surname><given-names>N</given-names></name>
<source>Molecular biology and evolution</source>
<volume>28</volume>, <fpage>849</fpage>–<lpage>857</lpage> (<year>2011</year>).<pub-id pub-id-type="pmid">20937735</pub-id></mixed-citation>
    </ref>
    <ref id="R13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><name><surname>Tishkoff</surname><given-names>SA</given-names></name><etal/><source>Science</source><volume>293</volume>, <fpage>455</fpage>–<lpage>462</lpage> (<year>2001</year>).<pub-id pub-id-type="pmid">11423617</pub-id></mixed-citation>
    </ref>
    <ref id="R14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><name><surname>Heffelfinger</surname><given-names>C</given-names></name><etal/><source>European Journal of Human Genetics</source><volume>22</volume>, <fpage>551</fpage>–<lpage>557</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24002163</pub-id></mixed-citation>
    </ref>
    <ref id="R15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><name><surname>Wilde</surname><given-names>S</given-names></name><etal/><source>Proceedings of the National Academy of Sciences</source><volume>111</volume>, <fpage>4832</fpage>–<lpage>4837</lpage> (<year>2014</year>).</mixed-citation>
    </ref>
    <ref id="R16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><name><surname>Coop</surname><given-names>G</given-names></name><etal/><source>PLoS Genet</source><volume>5</volume>, <fpage>e1000500</fpage>–<lpage>e1000500</lpage> (<year>2009</year>).<pub-id pub-id-type="pmid">19503611</pub-id></mixed-citation>
    </ref>
    <ref id="R17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><name><surname>Campbell</surname><given-names>CD</given-names></name><etal/><source>Nature genetics</source><volume>44</volume>, <fpage>1277</fpage>–<lpage>1281</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">23001126</pub-id></mixed-citation>
    </ref>
    <ref id="R18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><name><surname>Galinsky</surname><given-names>KJ</given-names></name>, <name><surname>Loh</surname><given-names>P-R</given-names></name>, <name><surname>Mallick</surname><given-names>S</given-names></name>, <name><surname>Patterson</surname><given-names>NJ</given-names></name> &amp; <name><surname>Price</surname><given-names>AL</given-names></name>
<source>The American Journal of Human Genetics</source>
<volume>99</volume>, <fpage>1130</fpage>–<lpage>1139</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27773431</pub-id></mixed-citation>
    </ref>
    <ref id="R19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><name><surname>Beleza</surname><given-names>S</given-names></name><etal/><source>PLoS Genet</source><volume>9</volume>, <fpage>e1003372</fpage>–<lpage>e1003372</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23555287</pub-id></mixed-citation>
    </ref>
    <ref id="R20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><name><surname>Cornelis</surname><given-names>MC</given-names></name><etal/><source>Molecular psychiatry</source><volume>20</volume>, <fpage>647</fpage>–<lpage>656</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25288136</pub-id></mixed-citation>
    </ref>
    <ref id="R21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><name><surname>Ferrer-Admetlla</surname><given-names>A</given-names></name>, <name><surname>Liang</surname><given-names>M</given-names></name>, <name><surname>Korneliussen</surname><given-names>T</given-names></name> &amp; <name><surname>Nielsen</surname><given-names>R</given-names></name>
<source>Mol Biol Evol</source>
<volume>31</volume>, <fpage>1275</fpage>–<lpage>1291</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">24554778</pub-id></mixed-citation>
    </ref>
    <ref id="R22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><name><surname>Pybus</surname><given-names>M</given-names></name><etal/><source>Bioinformatics</source><volume>31</volume>, <fpage>3946</fpage>–<lpage>3952</lpage> (<year>2015</year>).<pub-id pub-id-type="pmid">26315912</pub-id></mixed-citation>
    </ref>
    <ref id="R23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><name><surname>Garud</surname><given-names>NR</given-names></name>, <name><surname>Messer</surname><given-names>PW</given-names></name>, <name><surname>Buzbas</surname><given-names>EO</given-names></name> &amp; <name><surname>Petrov</surname><given-names>DA</given-names></name>
<source>PLoS Genet</source>
<volume>11</volume>, <fpage>e1005004</fpage> (<year>2015</year>).<pub-id pub-id-type="pmid">25706129</pub-id></mixed-citation>
    </ref>
    <ref id="R24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><name><surname>DeGiorgio</surname><given-names>M</given-names></name>, <name><surname>Huber</surname><given-names>CD</given-names></name>, <name><surname>Hubisz</surname><given-names>MJ</given-names></name>, <name><surname>Hellmann</surname><given-names>I</given-names></name> &amp; <name><surname>Nielsen</surname><given-names>R</given-names></name>
<source>Bioinformatics</source>
<volume>32</volume>, <fpage>1895</fpage>–<lpage>1897</lpage> (<year>2016</year>).<pub-id pub-id-type="pmid">27153702</pub-id></mixed-citation>
    </ref>
    <ref id="R25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><name><surname>Ronen</surname><given-names>R</given-names></name>, <name><surname>Udpa</surname><given-names>N</given-names></name>, <name><surname>Halperin</surname><given-names>E</given-names></name> &amp; <name><surname>Bafna</surname><given-names>V</given-names></name>
<source>Genetics</source>
<volume>195</volume>, <fpage>181</fpage>–<lpage>193</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23770700</pub-id></mixed-citation>
    </ref>
    <ref id="R26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><name><surname>Pavlidis</surname><given-names>P</given-names></name>, <name><surname>Zivkovic</surname><given-names>D</given-names></name>, <name><surname>Stamatakis</surname><given-names>A</given-names></name> &amp; <name><surname>Alachiotis</surname><given-names>N</given-names></name>
<source>Mol Biol Evol</source>
<volume>30</volume>, <fpage>2224</fpage>–<lpage>2234</lpage> (<year>2013</year>).<pub-id pub-id-type="pmid">23777627</pub-id></mixed-citation>
    </ref>
    <ref id="R27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>H</given-names></name>, <name><surname>Patterson</surname><given-names>N</given-names></name> &amp; <name><surname>Reich</surname><given-names>D</given-names></name>
<source>Genome Res</source>
<volume>20</volume>, <fpage>393</fpage>–<lpage>402</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20086244</pub-id></mixed-citation>
    </ref>
    <ref id="R28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><name><surname>Sabeti</surname><given-names>PC</given-names></name><etal/><source>Nature</source><volume>449</volume>, <fpage>913</fpage>–<lpage>918</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17943131</pub-id></mixed-citation>
    </ref>
    <ref id="R29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><name><surname>Sabeti</surname><given-names>PC</given-names></name><etal/><source>Nature</source><volume>419</volume>, <fpage>832</fpage>–<lpage>837</lpage> (<year>2002</year>).<pub-id pub-id-type="pmid">12397357</pub-id></mixed-citation>
    </ref>
    <ref id="R30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><name><surname>Nielsen</surname><given-names>R</given-names></name><etal/><source>Genome Res</source><volume>15</volume>, <fpage>1566</fpage>–<lpage>1575</lpage> (<year>2005</year>).<pub-id pub-id-type="pmid">16251466</pub-id></mixed-citation>
    </ref>
    <ref id="R31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>Y</given-names></name> &amp; <name><surname>Nielsen</surname><given-names>R</given-names></name>
<source>Genetics</source>
<volume>167</volume>, <fpage>1513</fpage>–<lpage>1524</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15280259</pub-id></mixed-citation>
    </ref>
    <ref id="R32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><name><surname>Alachiotis</surname><given-names>N</given-names></name>, <name><surname>Stamatakis</surname><given-names>A</given-names></name> &amp; <name><surname>Pavlidis</surname><given-names>P</given-names></name>
<source>Bioinformatics</source>
<volume>28</volume>, <fpage>2274</fpage>–<lpage>2275</lpage> (<year>2012</year>).<pub-id pub-id-type="pmid">22760304</pub-id></mixed-citation>
    </ref>
    <ref id="R33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><name><surname>Shriver</surname><given-names>MD</given-names></name><etal/><source>Hum Genomics</source><volume>1</volume>, <fpage>274</fpage>–<lpage>286</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15588487</pub-id></mixed-citation>
    </ref>
    <ref id="R34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><name><surname>Ewing</surname><given-names>G</given-names></name> &amp; <name><surname>Hermisson</surname><given-names>J</given-names></name>
<source>Bioinformatics</source>
<volume>26</volume>, <fpage>2064</fpage>–<lpage>2065</lpage> (<year>2010</year>).<pub-id pub-id-type="pmid">20591904</pub-id></mixed-citation>
    </ref>
    <ref id="R35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><name><surname>Nachman</surname><given-names>MW</given-names></name> &amp; <name><surname>Crowell</surname><given-names>SL</given-names></name>
<source>Genetics</source>
<volume>156</volume>, <fpage>297</fpage>–<lpage>304</lpage> (<year>2000</year>).<pub-id pub-id-type="pmid">10978293</pub-id></mixed-citation>
    </ref>
    <ref id="R36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><name><surname>Jensen-Seaman</surname><given-names>MI</given-names></name><etal/><source>Genome research</source><volume>14</volume>, <fpage>528</fpage>–<lpage>538</lpage> (<year>2004</year>).<pub-id pub-id-type="pmid">15059993</pub-id></mixed-citation>
    </ref>
    <ref id="R37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><name><surname>Gravel</surname><given-names>S</given-names></name><etal/><source>Proceedings of the National Academy of Sciences</source><volume>108</volume>, <fpage>11983</fpage>–<lpage>11988</lpage> (<year>2011</year>).</mixed-citation>
    </ref>
    <ref id="R38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><name><surname>Szpiech</surname><given-names>ZA</given-names></name> &amp; <name><surname>Hernandez</surname><given-names>RD</given-names></name>
<source>Molecular biology and evolution</source>
<volume>31</volume>, <fpage>2824</fpage>–<lpage>2827</lpage> (<year>2014</year>).<pub-id pub-id-type="pmid">25015648</pub-id></mixed-citation>
    </ref>
    <ref id="R39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><name><surname>Zerbino</surname><given-names>DR</given-names></name><etal/><source>Nucleic Acids Res</source> (<year>2017</year>).</mixed-citation>
    </ref>
    <ref id="R40">
      <label>40.</label>
      <mixed-citation publication-type="journal"><name><surname>International HapMap</surname><given-names>C</given-names></name><etal/><source>Nature</source><volume>449</volume>, <fpage>851</fpage>–<lpage>861</lpage> (<year>2007</year>).<pub-id pub-id-type="pmid">17943122</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<floats-group>
  <fig id="F1" orientation="portrait" position="float">
    <label>Figure 1</label>
    <caption>
      <p id="P40">Illustration and performance of the SAFE method. (<bold>a</bold>) The HAF score for haplotype <italic>h</italic> is the sum of the derived allele counts of the mutations on <italic>h</italic>. Carriers of the favored mutation have higher fraction of the total HAF score of the sample (high <italic>ϕ</italic>)<sup><xref rid="R6" ref-type="bibr">6</xref></sup>, and lower number of distinct haplotypes compared to non-carriers (low <italic>κ</italic>). (<bold>b</bold>) Schematic of a no-recombination (for exposition purposes) genealogy under a selective sweep. The mutations can be categorized as ‘non-carrier’ (gray), ‘ancestral to favored’ (turquoise) arising prior to the favored mutation, and ‘descendant to favored’ (blue) that arise on haplotypes carrying the favored mutations but after the favored mutation, and the favored mutation itself (red). In the right panels, simulations showing <italic>ϕ</italic> versus <italic>κ</italic> values for each variant in a neutral evolution and a selective sweep for 1000 simulations with favored allele frequency (<italic>ν</italic><sub>0</sub> = 0.5) and default values for other simulation parameters (see <xref rid="S1" ref-type="sec">Online Methods</xref>). The joint-distribution of <italic>ϕ</italic> and <italic>κ</italic>, in a selective sweep, changes in a dramatic but predictable manner that separates out non-carrier (gray), descendant (blue), and ancestral (turquoise) mutations from the favored (red) mutations. The SAFE score computes a normalized difference of the two statistics, <italic>ϕ</italic> and <italic>κ</italic>. (<bold>c</bold>) Performance (favored mutation rank) of SAFE compared to iHS and SCCT on 50 kbp windows with 1000 simulations per frequency bin. The simulations were performed with default parameter values (see <xref rid="S1" ref-type="sec">Online Methods</xref>) for a fixed population size with ongoing selective sweeps. The left panel combines all allele frequencies while the right panel shows median and mean ranks for replicates divided into four bins.</p>
    </caption>
    <graphic xlink:href="nihms-937763-f0001"/>
  </fig>
  <fig id="F2" orientation="portrait" position="float">
    <label>Figure 2</label>
    <caption>
      <p id="P41">Illustration of the iSAFE method. (<bold>a</bold>) The red-star, turquoise-triangle, and blue-square denote the favored, ancestral, and descendant mutations, respectively. As different windows have different genealogies due to recombination, the SAFE-score of a non-favored mutation <italic>e</italic> is relatively low when inserted in other windows. In contrast, the SAFE-score of the favored mutation is likely to dominate other mutations (<xref rid="SD3" ref-type="supplementary-material">Supplementary Note 1</xref>). (<bold>b</bold>) The Ψ<italic>e,w</italic> matrix for a 5 Mbp region around LCT gene in FIN population shows that the ‘shoulder’ of selection can extend for a few Mbp. The blue circle shows the location of the putative favored mutation rs4988235. (<bold>c</bold>) SAFE and iSAFE performance (rank distribution of favored mutation) as a function of window size with 1000 simulations per bin. The dashed (dotted) line represents median (quartile), and decays for large windows while iSAFE is robust to increase in window size.</p>
    </caption>
    <graphic xlink:href="nihms-937763-f0002"/>
  </fig>
  <fig id="F3" orientation="portrait" position="float">
    <label>Figure 3</label>
    <caption>
      <p id="P42">iSAFE performance. (<bold>a</bold>) The top left (right) panel is the Cumulative Distribution Function (CDF) of favored mutation rank (peak distance) for iSAFE and CMS scores. The lower panel shows the iSAFE performance (rank and peak distance distributions of favored mutation) as a function of favored allele frequency (<italic>ν</italic> ) in the target population (EUR). The dashed (dotted) line represents median (quartiles). All data is based on 1000 simulations of 5 Mbp genomic regions simulated using a model of human genome based on the human demography (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 14</xref>). The time of onset of selection was chosen at random (using the distribution in <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 14</xref>) after the out of Africa event, in the lineage of EUR population (as the target population). When the onset of selection is before split of EUR and EAS (&gt;23kya), both (EUR and EAS) are under selection. (<bold>b</bold>) iSAFE and CMS scores (top and bottom panels, respectively) on 4 well-characterized selective sweeps (<xref rid="SD2" ref-type="supplementary-material">Supplementary Fig 8</xref>; <xref rid="SD3" ref-type="supplementary-material">Supplementary Table 1</xref>). The rank of the putative favored mutation (red star) in 5 Mbp region is shown in top left corner. (<bold>c</bold>) iSAFE-scores on regions under selection. Top ranked iSAFE candidates are marked by blue squares when they match putative favored mutations, while turquoise circles represent new favored mutations suggested by iSAFE. All data-sets were chosen by taking a 5 Mbp window around the putative selected region, unless one side reached the telomere or centromere. (<bold>d</bold>) The GRM5-TYR region. The mutation rs672144 is ranked first by iSAFE and very well separated from rest of the mutations in 5 Mbp around it, in all non-African populations with high confidence (iSAFE &gt; 0.5, <italic>P</italic> ≪ 1.3e-8; <xref rid="SD2" ref-type="supplementary-material">Supplementary Fig. 10</xref>). The upper panel is haplotype plot with core mutation rs672144 on all 5008 haplotypes (2504 samples) of 1000GP. This plot shows carrier haplotypes of mutation rs672144 are conserved over a longer span than haplotypes in non-carriers which is a signal of selection<sup><xref rid="R8" ref-type="bibr">8</xref></sup>. Lower panel shows global frequencies of carrier haplotypes of mutation rs672144 (red, blue) and non-carrier haplotypes (gray). The evidence is consistent with an out of Africa selection on standing variation (soft sweep) with mutation rs672144 as the favored variant.</p>
    </caption>
    <graphic xlink:href="nihms-937763-f0003"/>
  </fig>
</floats-group>
